Customer Publication

Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing

Authors: Y. Tayyar et al.

Journal: Am J Cancer Res. (2021)

Institution: Griffith University

Research Areas: Cancer research

Cell Lines: HeLa (Cervical cancer cell line)

Summary: Human papillomavirus (HPV) is the main causative agent in cervical cancers. High-risk HPV cancers, including cervical cancer, are driven by major HPV oncogene E6 and E7, which promote uncontrolled cell growth and genomic instability. Authors tested if MLN8237 (Alisertib), an oral, selective inhibitor of AURKs, can improve tumor response when combined with either radiotherapy (RT) treatment or with a PI3K inhibitor BYL719 (Alpelisib). Results indicated that both RT and Alpelisib significantly improved Alisertib-mediated tumor killing, and the promising achieved results warrant further development of these combinations and potentially translating them to the clinics.

Keywords: HoloMonitor, Radiation, Alisertib, Alpelisib, aurora kinase, PI3K, cervical cancer, HPV, E7

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2